Carcinoid / Neuroendocrine Neoplasms

Regimen Options

Last Updated: 06/03/2024 See Details

	Evolent Pathways	Febrile Neutropenic Risk	Emetogenic Risk	References
LUNG AND THYMUS
	octreotide LAR (depot)	NCCN Guidelines® for Neuroendocrine Tumors V.3.2017. Rinke A, et al. J Clin Oncol. 2009;27(28):4656-63.
	octreotide SQ (non-depot)	NCCN Guidelines® for Neuroendocrine Tumors V.3.2017.
	lanreotide	Low	Low	NCCN Guidelines® for Neuroendocrine Tumors V.3.2017. Caplin ME et al. N Engl J Med . 2014 Jul 17;371(3):224-33
	everolimus	Low	Low	NCCN Guidelines® for Neuroendocrine Tumors V.3.2017. Yao JC, et al. New Engl J Med. 2011;364(6):514-23.
	carboplatin or cisplatin and etoposide	Intermediate	High	NCCN Guidelines® for Neuroendocrine Tumors V.3.2017. Chong CR et al. Lung Cancer . 2014 Nov;86(2):241-6
PANCREATIC (WELL-DIFFERENTIATED GRADE 1/2)
	octreotide LAR (depot)	NCCN Guidelines® for Neuroendocrine Tumors V.3.2017. Rinke A, et al. J Clin Oncol. 2009;27(28):4656-63.
	octreotide SQ (non-depot)	NCCN Guidelines® for Neuroendocrine Tumors V.3.2017
	lanreotide	Low	Low	NCCN Guidelines® for Neuroendocrine Tumors V.3.2017. Caplin ME et al. N Engl J Med . 2014 Jul 17;371(3):224-33
	sunitinib	Low	Low	NCCN Guidelines® for Neuroendocrine Tumors V.3.2017. Raymond E, et al. New Engl J Med. 2011;364(6):501-13.
	everolimus	Low	Low	NCCN Guidelines® for Neuroendocrine Tumors V.3.2017. Yao JC, et al. New Engl J Med. 2011;364(6):514-23.
	temozolomide and capecitabine	Low	Low	NCCN Guidelines® for Neuroendocrine Tumors V.3.2017. Raymond E et al. Cancer . 2011 Jan 15;117(2):268-75
	PPRT with Lutetium Lu 177 dotatate (Lutathera)	Low	Low	NCCN Guidelines® for Neuroendocrine Tumors V.3.2017. Strosberg J et al. N Engl J Med 2017; 376:125-135
GASTROINTESTINAL (WELL-DIFFERENTIATED GRADE 1/2)
	octreotide LAR (depot)	NCCN Guidelines® for Neuroendocrine Tumors V.3.2017. Rinke A, et al. J Clin Oncol. 2009;27(28):4656-63.
	octreotide SQ (non-depot)	NCCN Guidelines® for Neuroendocrine Tumors V.3.2017.
	everolimus	Low	Low	NCCN Guidelines® for Neuroendocrine Tumors V.3.2017. Yao JC, et al. New Engl J Med. 2011;364(6):514-23.
	PPRT with Lutetium Lu 177 dotatate (Lutathera)	Low	Low	NCCN Guidelines® for Neuroendocrine Tumors V.3.2017. Strosberg J et al. N Engl J Med 2017; 376:125-135
NEUROENDOCRINE CARCINOMA/LARGE OR SMALL CELL (EXTRAPULMONARY)
	carboplatin or cisplatin and etoposide	Intermediate	High	NCCN Guidelines® for Neuroendocrine Tumors V.3.2017. Frizziero M et al. Neuroendocrinology . 2019;109(2):100-112

LUNG AND THYMUS

Evolent Pathways

octreotide LAR (depot)

References

Evolent Pathways

octreotide SQ (non-depot)

References

Evolent Pathways

lanreotide

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Evolent Pathways

everolimus

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Evolent Pathways

carboplatin or cisplatin and etoposide

Febrile Neutropenic Risk

intermediate

Emetogenic Risk

high

References

PANCREATIC (WELL-DIFFERENTIATED GRADE 1/2)

Evolent Pathways

octreotide LAR (depot)

References

Evolent Pathways

octreotide SQ (non-depot)

References

Evolent Pathways

lanreotide

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Evolent Pathways

sunitinib

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Evolent Pathways

everolimus

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Evolent Pathways

temozolomide and capecitabine

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Evolent Pathways

PPRT with Lutetium Lu 177 dotatate (Lutathera)

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

GASTROINTESTINAL (WELL-DIFFERENTIATED GRADE 1/2)

Evolent Pathways

octreotide LAR (depot)

References

Evolent Pathways

octreotide SQ (non-depot)

References

Evolent Pathways

everolimus

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Evolent Pathways

PPRT with Lutetium Lu 177 dotatate (Lutathera)

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

NEUROENDOCRINE CARCINOMA/LARGE OR SMALL CELL (EXTRAPULMONARY)

Evolent Pathways

carboplatin or cisplatin and etoposide

Febrile Neutropenic Risk

intermediate

Emetogenic Risk

high

References

Pathways and Low-Value Regimens

Carcinoid / Neuroendocrine Neoplasms